We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

Fund managers haven’t disclosed any holdings of CHRS yet.

CHRS Hedge Fund Activity: Q1 2026 in Review

157 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2026, worth a combined $100M — up 37% from $72.8M a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new CHRS positions and 10 closed out — a net gain of 32 holders — while 46 added to existing stakes and 37 trimmed.

The largest buyer was Samsara BioCapital, opening a new position worth an estimated $6.09M. The largest seller was Tang Capital Management, cutting an estimated $1.49M.

  • 157 institutional investors held Coherus Oncology (CHRS) as of Q1 2026, up from 127 in Q4 2025.
  • Funds reported $100M of Coherus Oncology stock for Q1 2026, up 37% quarter-over-quarter.
  • 42 funds opened new Coherus Oncology positions in Q1 2026 and 10 closed out, a net change of +32 holders.
  • The largest Coherus Oncology buyer in Q1 2026 was Samsara BioCapital, an estimated $6.09M added.
  • The largest Coherus Oncology seller in Q1 2026 was Tang Capital Management, an estimated $1.49M sold.

Based on aggregated 13F filings for Q1 2026.